Cancer immunotherapy

Jump to navigation Jump to search

WikiDoc Resources for Cancer immunotherapy


Most recent articles on Cancer immunotherapy

Most cited articles on Cancer immunotherapy

Review articles on Cancer immunotherapy

Articles on Cancer immunotherapy in N Eng J Med, Lancet, BMJ


Powerpoint slides on Cancer immunotherapy

Images of Cancer immunotherapy

Photos of Cancer immunotherapy

Podcasts & MP3s on Cancer immunotherapy

Videos on Cancer immunotherapy

Evidence Based Medicine

Cochrane Collaboration on Cancer immunotherapy

Bandolier on Cancer immunotherapy

TRIP on Cancer immunotherapy

Clinical Trials

Ongoing Trials on Cancer immunotherapy at Clinical

Trial results on Cancer immunotherapy

Clinical Trials on Cancer immunotherapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cancer immunotherapy

NICE Guidance on Cancer immunotherapy


FDA on Cancer immunotherapy

CDC on Cancer immunotherapy


Books on Cancer immunotherapy


Cancer immunotherapy in the news

Be alerted to news on Cancer immunotherapy

News trends on Cancer immunotherapy


Blogs on Cancer immunotherapy


Definitions of Cancer immunotherapy

Patient Resources / Community

Patient resources on Cancer immunotherapy

Discussion groups on Cancer immunotherapy

Patient Handouts on Cancer immunotherapy

Directions to Hospitals Treating Cancer immunotherapy

Risk calculators and risk factors for Cancer immunotherapy

Healthcare Provider Resources

Symptoms of Cancer immunotherapy

Causes & Risk Factors for Cancer immunotherapy

Diagnostic studies for Cancer immunotherapy

Treatment of Cancer immunotherapy

Continuing Medical Education (CME)

CME Programs on Cancer immunotherapy


Cancer immunotherapy en Espanol

Cancer immunotherapy en Francais


Cancer immunotherapy in the Marketplace

Patents on Cancer immunotherapy

Experimental / Informatics

List of terms related to Cancer immunotherapy

Cancer immunotherapy is the use of the immune system to reject cancer. The main premise is stimulating the patient's immune system to attack the malignant tumor cells that are responsible for the disease. This can be either through immunization of the patient, in which case the patient's own immune system is trained to recognize tumor cells as targets to be destroyed, or through the administration of therapeutic antibodies as drugs, in which case the patient's immune system is recruited to destroy tumor cells by the therapeutic antibodies.

Since the immune system responds to the environmental factors it encounters on the basis of discrimination between self and non-self, many kinds of tumor cells that arise as a result of the onset of cancer are more or less tolerated by the patient's own immune system since the tumor cells are essentially the patient's own cells that are growing, dividing and spreading without proper regulatory control.


Cell surface receptors

This approach works by "targeting molecules whose (elevated) expression is (mostly) confined to cancer cells".

Many kinds of tumor cells display unusual antigens that are either inappropriate for the cell type and/or its environment, or are only normally present during the organisms' development (e.g. fetal antigens). Examples of such antigens include:

Immune checkpoint inhibitors

Immune checkpoint inhibitors work by "augmenting host immune recognition of genetically altered cancer cell epitopes to eliminate cancer cells by host immunity"


Monoclonal antibody therapy

Antibodies are a key component of the adaptive immune response, playing a central role in both in the recognition of foreign antigens and the stimulation of an immune response to them. It is not surprising therefore, that many immunotherapeutic approaches involve the use of antibodies. The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens such as the unusual antigens that are presented on the surfaces of tumors.

A number of therapeutic monoclonal antibodies have been approved for use in humans; approvals mentioned here are by the FDA.

Cancer immunotherapy:Monoclonal antibodies[1]
Antibody Brand name Approval date Type Target Approved treatment(s)
Alemtuzumab Campath 2001 humanized CD52 Chronic lymphocytic leukemia
Bevacizumab Avastin 2004 humanized vascular endothelial growth factor colorectal cancer
Cetuximab Erbitux 2004 chimeric epidermal growth factor receptor colorectal cancer
Gemtuzumab ozogamicin Mylotarg 2000 humanized CD33 acute myelogenous leukemia (with calicheamicin)
Ibritumomab tiuxetan Zevalin 2002 murine CD20 non-Hodgkin lymphoma (with yttrium-90 or indium-111)
Panitumumab Vectibix 2006 humanized epidermal growth factor receptor colorectal cancer
Rituximab Rituxan, Mabthera 1997 chimeric CD20 non-Hodgkin lymphoma
Trastuzumab Herceptin 1998 humanized ErbB2 breast cancer


Alemtuzumab is an anti-CD52 humanized IgG1 monoclonal antibody indicated for the treatment of Chronic lymphocytic leukemia(CLL), the most frequent form of leukaemia in Western countries.[2] The function of CD52 is unknown, but it is found on >95% of peripheral blood lymphocytes and monocytes. Upon binding to CD52, alemtuzumab initiates its cytotoxic effect by complement fixation and antibody-dependent cell-mediated cytotoxicity mechanisms. Alemtuzumab therapy is also indicated for T-prolymphocytic leukaemia (TPPL), for which no standard treatment exists. This is a highly aggressive tumour, with a median survival of 7.5 months.[3]


Bevacizumab is a humanized IgG1 monoclonal antibody which binds to and sterically interferes with the vascular endothelial growth factor-A (VEGF-A), preventing receptor activation. A marked increase in VEGF expression is thought to play a role in tumor angiogenesis. Bevacizumab is indicated for colon cancer; but has been applied to numerous other cancers in small scale studies, especially renal cell carcinoma. Results obtained showed that bevacizumab increased the duration of survival, progression-free survival, the rate of response and the duration of response in a statistically relevant manner.[4]


Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of the epidermal growth factor receptor (EGFR). It functions by competitively inhibiting ligand binding, thereby preventing EGFR activation, and is indicated for the treatment of colorectal cancer. Studies have also been carried out on numerous other malignancies, especially non-small cell lung cancer and head and neck cancer. As a single agent, cetuximab showed a response rate of 10.8% in patients with EGFR overexpressed metastatic colon cancer.[1] Other anti-EGFR monoclonal antibodies in development include: ABX-EGF, hR3, and EMD 72000. Although they hold significant promise for the future, as of yet none of the agents are currently beyond phase I clinical trials.

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is an “immuno-conjugate” of an anti-CD33 antibody chemically linked to calicheamicin, a cytotoxic agent. It is indicated for the treatment of acute myeloid leukaemia (AML). The patient group most likely to benefit from gemtuzumab is young adults, and trials have reported high complete responses (85%), when combined with intensive chemotherapy. There are minimal side-effects associated with Gemtuzumab therapy.[5]


Rituximab is a chimeric monoclonal antibody specific for CD20. CD20 is widely expressed on B-cells. Although the function of CD20 is relatively unknown it has been suggested that CD20 could play a role in calcium influx across plasma membrane, maintaining intracellular calcium concentration and allowing for the activation of B cells.[6] The exact mode of action of rituximab is also unclear, but it has been found to have a general regulatory effect on the cell cycle and on immune-receptor expression.[1] Experiments involving primates showed that treatment with anti-CD20 reduced peripheral B-cells by 98%, and peripheral lymph node and bone marrow B-cells by up to 95%.[7]


Trastuzumab is a monoclonal IgG1 humanized antibody specific for the epidermal growth factor receptor 2 protein (HER2). It received FDA-approval in 1998, and is clinically used for the treatment of breast cancer. The use of Trastuzumab is restricted to patients whose tumours over-express HER-2, as assessed by immunohistochemistry (IHC) and either chromogenic or Fluorescent in situ hybridisation (FISH), as well as numerous PCR-based methodologies.

HER-2 is a member of the epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases, and is normally involved in regulation of cell proliferation and differentiation.[8] Amplification or overexpression of HER-2 is present in 25-30% of breast carcinomas and has been associated with aggressive tumour phenotype, poor prognosis, non-responsiveness to hormonal therapy and reduced sensitivity to conventional chemotherapeutic agents.[9]

Adoptive immunotherapy (CAR T-Cell therapy)

Adoptive immunotherapy is a "form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy."[10]

Common targets of CAR-T therapy include:

  • CD19 antigen on B-lymphocytes and B-cell precursors (CART-19 therapy or CD19-directed CAR - CTL019).
  • B-Cell Maturation Antigen (BCMA protein) for treating myeloma

CAR T-Cell therapy has been studied in oncology for:

  • Refractory B-cell acute lymphoblastic leukemia (B-ALL) in children and young adults in a non-randomized study[11]
  • Refractory B-cell non-Hodgkin lymphoma (B-NHL) in adults in the ZUMA-1[12] non-randomized study and other studies[13]
  • Multiple myeloma in a non-randomized study[14]

A common drug toxicity is cytokine release syndrome (CRS) or cytokine storm.

CAR T-Cell therapy is expensive with drug costs alone described as $475,000 for tisagenlecleucel for B-cell acute lymphoblastic leukemia (B-ALL) and $373,000 for tisagenlecleucel and axicabtagene ciloleucel for B-cell non-Hodgkin lymphoma (B-NHL)[15]. "Critics argue that tisagenlecleucel’s $475,000 price tag is unaffordable and unjustifiable given the taxpayer-supported basic research underpinning its development"[16].

CAR T-cell therapy may also have a role in removing fibrosis in non-malignant fibrotic diseases[17].


Radioimmunotherapy involves the use of radioactively conjugated murine antibodies against cellular antigens. Most research currently involved their application to lymphomas, as these are highly radio-sensitive malignancies. To limit radiation exposure, murine antibodies were especially chosen, as their high immunogenicity promotes rapid clearance from the body.

Ibritumomab tiuxetan

Ibritumomab is a murine antibody chemically linked to tiuxetan, which chelates Yttrium-90. 90Y is a beta radiator, has a half-life of 64 h and a tissue penetration of 1-5 millimetres. Its use has been investigated, primarily in the treatment of follicular lymphoma.[18]


Tositumomab is a murine IgG2a anti-CD20 antibody and is covalently bound to Iodine 131. 131I emits both beta and gamma radiation, and is broken down rapidly in the body.[19] Clinical trials have established the efficacy of tositumomab in patients with relapsed follicular lymphoma.[20]

Advances in immunotherapy

The development and testing of second generation immunotherapies are already under way. While antibodies targeted to disease-causing antigens can be effective under certain circumstances, in many cases, their efficacy may be limited by other factors. In the case of cancer tumors, the microenvironment is immunosuppressive, allowing even those tumors that present unusual antigens to survive and flourish in spite of the immune response generated by the cancer patient, against his or her own tumor tissue. Certain members of a group of molecules known as cytokines, such as Interleukin-2 also play a key role in modulating the immune response, and have been tried in conjunction with antibodies in order to generate an even more devastating immune response against the tumor. While the therapeutic administration of such cytokines may cause systemic inflammation, resulting in serious side effects and toxicity, a new generation of chimeric molecules consisting of an immune-stimulatory cytokine attached to an antibody that targets the cytokine's activity to a specific environment such as a tumor, are able to generate a very effective yet localized immune response against the tumor tissue, destroying the cancer-causing cells without the unwanted side-effects. A different type of chimeric molecule is an artificial T cell receptor.

The targeted delivery of cytokines by anti-tumor antibodies is one example of using antibodies to delivery payloads rather than simply relying on the antibody to trigger an immune response against the target cell. Another strategy is to deliver a lethal radioactive dose directly to the target cell, which has been utilized in the case of the Zevalin® therapeutic. A third strategy is to deliver a lethal chemical dose to the target, as used in the Mylotarg® therapeutic. Engineering the antibody-payload pair in such a way that they separate after entry into a cell by endocytosis can potentially increase the efficacy of the payload. One strategy to accomplish this is the use of a disulfide linkage which could be severed by the reducing conditions in the cellular interior. However, recent evidence suggests that the actual intracellular trafficking of the antibody-payload after endocytosis is such to make this strategy not generally applicable. Other potentially useful linkage types include hydrazone and peptide linkages.[21]

Topical immunotherapy

Dermatologists use new creams and injections in the management of benign and malignant skin tumors. Topical immunotherapy utilizes an immune enhancement cream (imiquimod) which is an interferon producer causing the patient's own killer T cells to destroy warts, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, cutaneous T cell lymphoma, and Superficial spreading melanoma. Injection immunotherapy uses mumps, candida or trichophytin antigen injections to treat warts (HPV induced tumors).

See also

External links


  1. 1.0 1.1 1.2 Waldmann, Thomas A. (2003). "Immunotherapy: past, present and future". Nature Medicine. 9: 269&ndash, 277.
  2. Byrd JC, Stilgenbauer S, Flinn IW. Chronic Lymphocytic Leukemia. Hematology (Am Soc Hematol Educ Program) 2004: 163-183. Date retrieved: 26/01/2006.
  3. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-213.
  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
  5. De Angelo D, Stone R, Durant S, et al. Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials. Blood 2003; 102: 100a [abstract].
  6. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
  7. Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development. Oncogene 1999; 18: 3481-3490.
  8. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
  9. Anonymous (2023), Adoptive immunotherapy (English). Medical Subject Headings. U.S. National Library of Medicine.
  10. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H; et al. (2018). "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia". N Engl J Med. 378 (5): 439–448. doi:10.1056/NEJMoa1709866. PMC 5996391. PMID 29385370.
  11. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA; et al. (2017). "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma". N Engl J Med. 377 (26): 2531–2544. doi:10.1056/NEJMoa1707447. PMC 5882485. PMID 29226797.
  12. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö; et al. (2017). "Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas". N Engl J Med. 377 (26): 2545–2554. doi:10.1056/NEJMoa1708566. PMC 5788566. PMID 29226764.
  13. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D; et al. (2019). "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma". N Engl J Med. 380 (18): 1726–1737. doi:10.1056/NEJMoa1817226. PMID 31042825.
  14. Jacobson C, Emmert A, Rosenthal MB (2019). "CAR T-Cell Therapy: A Microcosm for the Challenges Ahead in Medicare". JAMA. doi:10.1001/jama.2019.10194. PMID 31355862.
  15. Rosenbaum L (2017). "Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy". N Engl J Med. 377 (14): 1313–1315. doi:10.1056/NEJMp1711886. PMID 28902570.
  16. Hill JA (2019). "When the CAR Targets Scar". N Engl J Med. 381 (25): 2475–2476. doi:10.1056/NEJMcibr1912586. PMID 31851806.
  17. Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2004; 22: 6519 [abstract].
  18. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin’s Lymphoma. Clin Med Res 2005; 3: 157-165.
  19. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
  20. Austin C.D.; et al. (2005). "Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates". Proc Natl Acad Sci U S A. 102 (50): 17987&ndash, 17992.


lt:Imunoterapija sl:Biološka zdravila